Abstract: The control unit operates the stirring device sequentially in a defiberization operating mode, a transition operating mode, and a dilution operating mode. In the defiberization operating mode, the stirring blade is rotated at the revolution speed for defiberization of waste paper in the disaggregating water stored in the stirring chamber to generate a waste paper pulp slurry. In the transition operating mode, the dilution water from the water supply unit is supplied to the waste paper pulp slurry while rotating the stirring blade at the revolution speed for defiberization to stir the waste paper pulp slurry. In the dilution operating mode, the dilution water from the water supply unit is supplied to the waste paper pulp slurry while rotating the stirring blade at the revolution speed for stirring, lower than the revolution speed for defiberization, to stir the waste paper pulp slurry.

Abstract: In order to promote solubilization or suspension of 4-oxo-8-[4-(4-phenylbutoxy)benzoylamino]-2-(tetrazol-5-yl)-4H-1-benzopyran or its hydrate (pranlukast) in water, at least one component selected from surfactants, water-soluble cellulose derivatives and water-soluble vinyl polymers is formulated together with pranlukast. Thus, it is possible to provide an aqueous liquid pharmaceutical composition containing higher concentration of pranlukast and having good properties.

Abstract: An ophthalmic suspension comprising difluprednate as an active ingredient. The ophthalmic suspension of the present invention shows superior antiinflammatory action and antiallergic action by local administration. Accordingly, the suspension of the present invention is useful for the treatment and prevention of disorders of the eye, such as allergic conjunctivitis, vernal conjunctivitis, blepharitis marginalis, catarrhal conjunctivitis and uveitis.